Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis

Patel S, Martin MT, Flamm SL. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis. Liver Int [Internet]. 2021;41(12):3024–3027. https://doi.org/10.1111/liv.15075

Publication Type:

Journal Article

Authors:

Patel, S; Martin, MT; Flamm, SL

Source:

Liver Int, Volume 41, Issue 12, p.3024–3027 (2021)

URL:

https://doi.org/10.1111/liv.15075

Keywords:

Cirrhosis, decompensated, Direct-acting antivirals, hepatitis C virus, Retreatment, salvage therapy, sofosbuvir, velpatasvir, voxilaprevir

Cited On:

External Third-party Web Link:

https://pubmed.ncbi.nlm.nih.gov/34592051/

Export Citation:
RIS Format
Top